- Home
- MUE vs CDXS Comparison
MUE vs CDXS Comparison
Compare MUE & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUE
- CDXS
- Stock Information
- Founded
- MUE 1999
- CDXS 2002
- Country
- MUE United States
- CDXS United States
- Employees
- MUE N/A
- CDXS N/A
- Industry
- MUE Investment Bankers/Brokers/Service
- CDXS Major Chemicals
- Sector
- MUE Finance
- CDXS Industrials
- Exchange
- MUE Nasdaq
- CDXS Nasdaq
- Market Cap
- MUE 210.6M
- CDXS 201.3M
- IPO Year
- MUE N/A
- CDXS 2010
- Fundamental
- Price
- MUE $9.50
- CDXS $2.25
- Analyst Decision
- MUE
- CDXS Buy
- Analyst Count
- MUE 0
- CDXS 2
- Target Price
- MUE N/A
- CDXS $11.00
- AVG Volume (30 Days)
- MUE 62.6K
- CDXS 1.0M
- Earning Date
- MUE 01-01-0001
- CDXS 05-14-2025
- Dividend Yield
- MUE 4.09%
- CDXS N/A
- EPS Growth
- MUE N/A
- CDXS N/A
- EPS
- MUE N/A
- CDXS N/A
- Revenue
- MUE N/A
- CDXS $49,815,000.00
- Revenue This Year
- MUE N/A
- CDXS $2.41
- Revenue Next Year
- MUE N/A
- CDXS $34.28
- P/E Ratio
- MUE N/A
- CDXS N/A
- Revenue Growth
- MUE N/A
- CDXS N/A
- 52 Week Low
- MUE $8.53
- CDXS $1.90
- 52 Week High
- MUE $10.17
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- MUE 39.32
- CDXS 42.74
- Support Level
- MUE $9.48
- CDXS $2.30
- Resistance Level
- MUE $9.66
- CDXS $2.56
- Average True Range (ATR)
- MUE 0.12
- CDXS 0.20
- MACD
- MUE -0.01
- CDXS -0.02
- Stochastic Oscillator
- MUE 12.50
- CDXS 40.54
About MUE Blackrock MuniHoldings Quality Fund II Inc.
BlackRock MuniHoldings Quality Fund II Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. The fund seeks to achieve its investment objective by investing in long-term, investment-grade municipal obligations exempt from U.S. federal income taxes.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.